MAESTrO: CADTH calls for patient input on a new submission from Celgene for Otezla

Posted by Michael Wonder on 30 Jan 2016

CADTH calls for patient input on a new submission from Celgene for Otezla

29 January 2016 - CADTH has received notice of a pending resubmission from Celgene for Otezla (apremilast) for use by patients with moderate to severe plaque psoriasis.

For more details, go to: https://www.cadth.ca/apremilast-6

Posted by:

Michael Wonder

Posted in:

Medicine , Health technology assessment , Canada